The Technical, Legal, and Political Minefield of Commercializing Stem Cells

Stem cells are primitive cells found in all multi-cellular organisms and are characterized by self-renewal and the capacity to differentiate into any mature cell type. However, it is this primitive nature that intrinsically makes commercializing stem cells a technical, legal and political minefield.

Topics: Biotechnology

Projected 2015 Trends in the Healthcare Industry

Healthcare market research publisher Kalorama Information has identified the top five trends in the healthcare field that made an impact in 2014 and will continue to be an influence throughout 2015. Kalorama compiled its list based on news events, growth rates of markets the firm studied in 2014, and information requests the firm receives from industry participants. 

Topics: Diagnostics Biotechnology Pharmaceuticals Healthcare Medical Devices

Cord Blood Industry: Key Benchmarks to Track (and Why You Should Care)

Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the global cord blood market has matured substantially over the past few years, creating both serious threats and novel opportunities. 

Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.

Topics: Biotechnology

U.S. Biomarker Market, Application in Drug Development

Drug development companies across the world have identified biomarkers as the effective solution to new product developments. The field of system biology provides theoretical and statistical tools for evaluating complicated clinical data. It allows access to molecular profiling information and explains facts related to biology in an orderly manner.

Topics: Biotechnology

Induced Pluripotent Stem Cells (iPSC): 3 Major Market Forces (And Why You Should Care)

The induced pluripotent stem cell (iPSC) market first emerged in 2006, when iPSC technology was pioneered by Shinya Yamanaka’s lab at Kyoto University in Japan. The shocking discovery that the introduction of four transcription factors into adult cells could convert them into pluripotent stem cells sent waves of excitement throughout the scientific community. This landmark event came to represent one of the greatest stem cell research discoveries of all time and was memorialized in 2012, when Dr. Yamanaka and Sir John Gurdon were awarded the Nobel Prize "for the discovery that mature cells can be reprogrammed to become pluripotent.” 

Topics: Biotechnology

The Business of Commercializing Induced Pluripotent Stem Cells (iPSCs)

As a provider of stem cell products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition. To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which they could be commercialized.

Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.

Topics: Biotechnology

Market Research Publisher Spotlight: MarketsandMarkets partners with over 700 publishers to offer customers the most comprehensive collection of diverse business intelligence. Each publisher has its own story and offers unique and insightful perspective into the industries they cover. This week, is spotlighting global, multi-industry information provider MarketsandMarkets. Read on to learn more about MarketsandMarkets and their products.

Topics: Food & Beverage Materials & Chemicals E-commerce & IT Outsourcing Biotechnology Manufacturing & Construction Energy & Resources Pharmaceuticals Consumer Electronics Telecommunications & Wireless Healthcare Medical Devices

Stem Cell Market Intelligence Reveals Effortless Ways to Profit

Whether you already supply stem cell research products or you wish to expand your product line, you’re aware that the market is continually increasing in size and competitiveness. You need to make effective product development decisions, sell more effectively to scientists, generate improved revenues, and take market share from your competition. Without strategic guidance on which to base your actions, you can find yourself in a difficult position.

New products that don’t sell well are costly mistakes, and offering products that can’t out-compete your competitors’ alternatives is certain to reduce the value of your company within the minds of your prospective clients.  On the other hand, repeatedly launching high-demand products and skillfully addressing the unmet needs of your clients is certain to position you as a market leader.

Topics: Biotechnology

How Market Research Serves the Unique Needs of Industry Investors

When it comes to market research, people automatically think of how it can serve the needs of the behemoth corporations or the hopeful start-ups. But, there are numerous market research customers that aren't quite the first to mind but are certainly extremely interested users of research. The role of an industry investor may seem simple to the average person: invest in a profitable company, market segment, industry, etc. and make loads of money. However, nothing is ever quite that simple, and investing is certainly no different. So, let's take a look at insights from leading market research publisher in the stem cell industry, BioInformant Worldwide, L.L.C., to see an example of how industry investors can best use market research to make quick and educated decisions for increased profit.

Topics: Market Research Strategy Biotechnology

3 Key Trends You Must Know to Profit from Stem Cell Products

The market for stem cell products and technologies is a rapidly evolving industry, largely because stem cells are a relatively recent, yet highly lucrative, discovery. While the first mouse embryonic stem cells were derived from embryos in 1981, it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts. In 2006, induced pluripotent stem cells were produced for the first time from mouse cells, and, in 2007, they were produced from human cells. Furthermore, it was not until 2008 that the first full transplant of a human organ grown from adult stem cells was performed when a section of a trachea was transplanted into a woman in Spain.

Topics: Biotechnology